5 products found
PharmAbcine Inc. Products
-
Core Technology
PharmAbcine has its own HuPhage library and innovative selection system. This technology provides therapeutic antibodies for a wide spectrum of indications in oncology, immuno-oncology, ophthalmology, pulmonology and etc.. PharmAbcine`s advanced 3G expression system accommodates high levels of antibody production and steady reproducibility. With these cutting-edge technology platforms, it provides state of the art antibody generation services.
-
PharmAbcine - Fully Human Antibody Library (HuPhage Library)
PharmAbcine’s fully human antibody library provides the diversity of antibody candidates for target antigens, ensuring highest success rates of developing therapeutic antibodies for various indications. Our unique and diverse antibody repertoires are constructed by recombination of V gene segments and DJ gene segments in human B-cell derived antibody heavy chains, generating more than 100 billion antibodies in combination with light chain sequences. ...
-
Pipeline
-
Olinvacimab - Model TTAC-0001 - Anti-Angiogenic Antibody
Olinvacimab is an anti-angiogenic antibody that neutralizes the VEGF/VEGFR2 pathway, thus inhibiting tumor growth and ...
-
PharmAbcine - Model PMC-309 - Engineered Monoclonal Antibody
PMC-309 is an engineered monoclonal antibody that targets the negative immune checkpoint human VISTA (V-domain Ig suppressor of T cell activation). It indirectly promotes T cells' immune responses by inhibiting VISTA-expressing immunosuppressive cells such as MDSCs (Myeloid-Derived Suppressor Cells) which suppress T cell inactivation and ...
-
PharmAbcine - Model PMC-402 - Monoclonal Antibody
PMC-402 is a monoclonal antibody that targets the human TIE2 that regulated activation, proliferation, and repolarization of Tie2 expressing macrophages, resulting in T cell activation. It binds to TIE2 expressing macrophages that activate T cells in the tumor microenvironment ...
-
PharmAbcine - Model PMC-403 - Monoclonal Antibody
PMC-403 is a monoclonal antibody that targets the human TIE2 that regulate the angiogenesis and vessel maturation in endothelial cells. It binds to TIE2 expressing endothelial cells and normalize VEGF-induced pathological leaky blood vessels in eyes and TME (tumor ...